Dehydroepiandrosterone and biologics in the treatment of systemic lupus erythematosus.
Our understanding of the immune system in health and disease has greatly increased over this past decade. An outgrowth of this burgeoning knowledge has been the discovery of novel strategies to treat a variety of autoimmune diseases. As a result, significant advances have been made in the treatment of arthritis with a half-dozen new treatments approved between September, 1998 and November, 1999. Although no new therapies have been approved for the treatment of systemic lupus erythematosus (SLE), this decade has witnessed an unprecedented amount of activity in drug development for this disease. This article specifically addresses the current status of drug development in the area of hormonal and biologic therapies for SLE.
Furie
R
R
Associate Professor of Clinical Medicine, Division of Rheumatology and Allergy-Clinical Immunology, North Shore University Hospital, 300 Community Drive, Manhasset, NY 11030, USA. furie@nshs.edu
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D001688:Biological Products / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003687:Dehydroepiandrosterone / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D009841:Oligonucleotides / Q000008:administration & dosage*; D011379:Prognosis; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D001688:Biological Products; D009841:Oligonucleotides; D003687:Dehydroepiandrosterone; C094104:abetimus